Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 21;7(7):FSO717.
doi: 10.2144/fsoa-2021-0016. eCollection 2021 Aug.

Serum thymidine kinase 1 protein concentration for predicting early progression and monitoring the response to TACE in hepatocellular carcinomas: a network meta-analysis

Hongbo Ma  1 , Ailian Hei  1 , Ji Zhou  1 , Ellen He  1 , Sven Skog  1 , Jin Li  1
Affiliations

Serum thymidine kinase 1 protein concentration for predicting early progression and monitoring the response to TACE in hepatocellular carcinomas: a network meta-analysis

Hongbo Ma et al. Future Sci OA. .

Abstract

Aim: A meta-analysis was conducted to evaluate the clinical significance of serum thymidine kinase 1 protein concentration (STK1p) in distinguishing between hepatocellular carcinomas (HCC) and non-HCC for predicting early progression and monitoring the response to transarterial chemoembolization in HCC.

Materials & methods: A total of 24 eligible studies were included, containing 1849 HCC patients and 1069 healthy subjects.

Results: The STK1p level significantly increased from normal controls to benign/pre-HCC and HCC (p < 0.0001). STK1p also increased significantly in sub-malignant groups: control being the lowest, followed consecutively by hepatic hemangioma, hepatitis B virus infection and hepatic cirrhosis (p < 0.05). After 1 month of transarterial chemoembolization treatment, STK1p level declined significantly, by 44.4% (p < 0.0001).

Conclusion: STK1p is a useful prognostic biomarker in HCC.

Keywords: HCC; NMA; STK1p; TACE; TK1; pre-HCC.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure J Zhou is the owner the company that produces the biomarker TK1 used in this meta-analysis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. Flow chart of literature selection for the network meta-analysis.
Figure 2.
Figure 2.. Forest plots of TK1.
(A) Forest plots of healthy subjects and HCCs. (B) Forest plots of benign liver disease patients and HCCs. (C) Forest plots of HCCs before and one month after TACE. *In Table 1, there were two separate patient groups which were treated with different types of chemotherapy. Each patient group included 45 cases. Black diamond indicates the mean value. HCC: Hepatocellular carcinoma; IV: Inverse variance; SD: Standard deviation; TACE: Transarterial chemoembolization.
Figure 3.
Figure 3.. Concentration of TK1 in serum.
Comparison of STK1p level among controls, hepatic benign/pre-HCC and HCC (A); Comparison of STK1p level among controls, HH, HBV infections, HC and HCC (B); Comparison of STK1p levels before and after TACE treatment in HCC (C). HBV: Hepatitis B virus; HC: Hepatic cirrhosis; HCC: Hepatocellular carcinoma; HH: Hepatic hemangiomas; STK1p: Serum thymidine kinase 1 protein concentration; TACE: Transarterial chemoembolization.
Figure 4.
Figure 4.. (A) Plots of the sensitivity between the controls and HCC group.
(B) Plots of the sensitivity between benign + pre-HCC and HCC. (C) Plots of the sensitivity between before and after TACE treatment in HCC. HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization.
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185, countries. CA Cancer J. Clin. 68(6), 394–424 (2018). - PubMed
    1. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 383(9930), 1749–1761 (2014). - PubMed
    1. Sartorius K, Swadling L, An P et al. The multiple roles of hepatitis B virus X protein (HBx) dysregulated microrna in hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) and immune pathways. Viruses 12(7), 746 (2020). - PMC - PubMed
    1. Chen ZQ, Xie H, Hu MM et al. Recent progress in treatment of hepatocellular carcinoma. Am. J. Cancer Res. 10(9), 2993–3036 (2020). - PMC - PubMed
    1. Krishan S, Dhiman RK, Kalra N et al. Joint consensus statement of the Indian National Association for study of the liver and indian radiological and imaging association for the diagnosis and imaging of hepatocellular carcinoma incorporating liver imaging reporting and data system. J. Clin. Exp. Hepatol. 9(5), 625–651 (2019). - PMC - PubMed

LinkOut - more resources